News >

Options Continue to Emerge for Transplant-Ineligible Multiple Myeloma

Angelica Welch
Published: Thursday, Apr 26, 2018

Nitya Nathwani, MD

Nitya Nathwani, MD
Although autologous stem cell transplant (ASCT) remains a backbone of treatment for patients with multiple myeloma, therapeutic options for those who are ineligible for transplant are growing, according to Nitya Nathwani, MD.

Results from the SWOG S0777 study published in 2016 established lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) as the standard of care for the frontline treatment of patients with myeloma. The RVd-modified, or “lite” regimen—in which lenalidomide, bortezomib, and dexamethasone are used in markedly lower doses—is being used in some older patients with myeloma, he said. The dose reduction makes the triplet more tolerable, while still providing benefit to frailer patients who are not eligible for ASCT.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication